deaths (OS)

mHNSCC - L1 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - all population

versus cetuximab plus platin plus 5FU
pembrolizumab alone vs. cetuximab plus platin plus 5FU 1 certainty unassessable-16%
pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU 1 certainty unassessablestatistically conclusive-21%